Clinical trial NCT06696261: A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
Official title: A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled Phase III Clinical Trial on the Efficacy and Safety of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome (Intermingled Cold and Heat).
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Postprandial Distress Syndrome
Lead sponsor: Tasly Pharmaceutical Group Co., Ltd
Sponsor class: INDUSTRY
First posted: 2024-11-20
Enrollment: 342
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are:

1. Based on the Response rate of postprandial distress syndrome participants, evaluate whether the efficacy of Lianxiaxiaopi Granules is superior to placebo.
2. Evaluate the efficacy of Lianxiaxiaopi Granules in improving symptom of postprandial distress syndrome.
3. Evaluating the safety of Lianxiaxiaopi Granules in postprandial distress syndrome participants.


Eligibility criteria: Inclusion Criteria:

1. Age 18 to 65 years old (including boundary value), gender is not limited;
2. meet the diagnostic criteria for postprandial distress syndrome (Rome IV.);
3. Meet the syndrome differentiation standards of Traditional Chinese Medicine for cold and heat miscellaneous syndromes;
4. NRS score of at least one symptom of postprandial distress syndrome (postprandial fullness, discomfort, early satiety) in the screening period and baseline period≥ 4 points; and did not have moderate/severe epigastric pain syndrome (mid-epigastric burning sensation and mid-upper quadrant pain both \< 4 points);
5. Those who did not have organic abnormal changes in the results of gastroscopy (including no abnormalities in gastroscopy, chronic non-atrophic gastritis/chronic superficial gastritis with erythema grade I and/or erosion that was flat and only grade I);
6. Negative Helicobacter pylori test in 13C/14C breath test during the screening period;
7. Voluntarily participate in clinical trials, sign informed consent, and understand and comply with research procedures.

Exclusion Criteria:

1. Those who have undergone Helicobacter pylori eradication treatment within 6 months before screening;
2. Gastric mucosal erythema grade II or above, erosion is bulge or grade II or above, or accompanied by bleeding, bile reflux, ≥ 3 inflammatory polyps and other manifestations, or combined with pathological diagnosis of chronic atrophic gastritis, hyperplastic polyps, glandular polyps, etc.; or those who have been clearly diagnosed with dyspepsia caused by organic diseases of the digestive system, such as digestive tract tumors, hepatobiliary and pancreatic diseases, inflammatory bowel diseases, etc.; or those who have other diseases that affect the evaluation of dyspepsia-related symptoms in the past, such as reflux esophagitis, peptic ulcer, gastrointestinal bleeding, intestinal obstruction, etc.;
3. Those who have been diagnosed with systemic diseases that seriously affect the function of the digestive tract, such as hyperthyroidism or hypothyroidism, diabetes, chronic renal insufficiency, connective tissue diseases, etc.;
4. Patients with severe cardiovascular and cerebrovascular, liver, lung, kidney, blood or systemic diseases that affect their survival; or patients with severe mental illness in the past, such as moderate or severe depression/anxiety/bipolar disorder, etc.;
5. Those who have a history of major abdominal surgery in the past, which may affect gastrointestinal function (except for appendectomy, cesarean section, endoscopic colon polyp resection and other surgeries that do not affect digestive function);
6. Patients with abnormal liver function (ALT or AST \>1.5 times the upper limit of normal) or abnormal renal function test (Cr\> upper limit of normal);
7. Glycosylated hemoglobin ≥ 6.5% or fasting blood glucose ≥7mmol/L during the screening period;
8. Use of drugs or treatments that may have an impact on the effectiveness assessment of the trial drug within 2 weeks before screening (such as acid/antacids, gastrointestinal motility drugs, digestive enzymes, gastric mucosal protectors, antiemetics, antispasmodics, macrolide antimicrobials, azole antifungals, non-steroidal anti-inflammatory drugs, glucocorticoids, anti-anxiety and depressants, analgesics, sedatives; as well as traditional Chinese medicine decoctions, proprietary Chinese medicines and acupuncture treatments for the treatment of functional dyspepsia, etc.);
9. Pregnant and lactating women, who have a birth plan within one month after enrollment and the end of the trial;
10. Those who suspect or have a history of alcohol or drug abuse;
11. Participated in other clinical trials within 1 month before screening;
12. Those who are suspected or known to be allergic to the ingredients of this medicine;
13. According to the judgment of the investigator, it is not suitable to participate in this study.

Primary outcomes:
measure: Postprandial distress syndrome response rate
timeFrame: The end of Week 8
Secondary outcomes:
measure: postprandial distress syndrome score change from baseline
timeFrame: The end of Week 8
measure: single symptom response rate
timeFrame: The end of Week 8
measure: the change value of single symptom score from baseline
timeFrame: The end of Week 8
measure: the change from baseline in epigstric pain syndrome score
timeFrame: The end of Week 8
measure: epigastric pain syndrome response rate
timeFrame: The end of Week 8
measure: the change from baseline in the total score of TCM
timeFrame: The end of Week 8
measure: the change value of TCM single symptom score from baseline
timeFrame: The end of Week 8
measure: TCM syndrome integral effective rate
timeFrame: The end of Week 8
measure: the grade change of TCM single symptom from baseline
timeFrame: The end of Week 8
measure: the proportion of subjects with sustained remission and no exacerbation of single symptoms at 12W compared with 8W
timeFrame: The end of Week 12
Other outcomes:
Locations:
city: Beijing
country: China
facility: Guang'anmen Hospital, China Academy of Chinese Medical Sciences
state: Beijing
city: Lanzhou
country: China
facility: Gansu Provincial Hospital of Traditional Chinese Medicine
state: Gansu
city: Guiyang
country: China
facility: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
state: Guizhou
city: Shijiazhuang
country: China
facility: Hebei Provincial Hospital of Traditional Chinese Medicine
state: Hebei
city: Xingtai
country: China
facility: The Second Affiliated Hospital of Xingtai Medical College
state: Hebei
city: Baoding
country: China
facility: Baoding No. 1 Hospital of Traditional Chinese Medicine
state: Heibei
city: Luoyang
country: China
facility: The First People's Hospital of Luoyang City
state: Henan
city: Changchun
country: China
facility: The Affiliated Hospital of Changchun University of Traditional Chinese Medicine
state: Jilin
city: Shenyang
country: China
facility: General Hospital of the Northern Theater of the Chinese People's Liberation Army
state: Liaoning
city: Shenyang
country: China
facility: The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
state: Liaoning
city: Shanghai
country: China
facility: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
state: Shanghai
city: Xianyang
country: China
facility: The Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
state: Shanxi
city: Chendu
country: China
facility: West China Hospital Sichuan University
state: Sichuan
city: Chengdu
country: China
facility: The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
state: Sichuan
city: Tianjin
country: China
facility: The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
state: Tianjin
city: Kunming
country: China
facility: The First Affiliated Hospital of Kunming Medical University
state: Yunnan
city: Hangzhou
country: China
facility: Zhejiang Provincial Hospital of Traditional Chinese Medicine
state: Zhejiang
city: Wenzhou
country: China
facility: Wenzhou Hospital of Traditional Chinese Medicine
state: Zhejiang
Study officials:
References: